Calidi Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLDI research report →
Range $2 – $9
Price Chart
About the company
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents.
- CEO
- Eric E. Poma
- IPO
- 2021
- Employees
- 29
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on CLDI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.64M
- P/E
- -0.02
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.46
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -372.86%
- ROIC
- -347.09%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,651,000+0.0%
- Op Income
- $-20,240,000
- Net Income
- $-19,906,000+10.1%
- EPS
- $-95.20+83.3%
- OCF Growth
- -8.1%
- FCF Growth
- -8.6%
- 52W High
- $27.84
- 52W Low
- $1.00
- 50D MA
- $1.36
- 200D MA
- $6.20
- Beta
- 1.33
- RSI (14)
- 33
- Avg Volume
- 260.06K
No earnings-call transcripts are available for CLDI yet.
- Free Float
- 99.1%
- Shares Outstanding
- 2.58M
- Float Shares
- 2.56M
of shares held by institutions
29 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Geode Capital Management, LLC | 114.55K | ▲ 51.53K |
| Hightower Advisors, LLC | 83.52K | 0 |
| Jane Street Group, LLC | 54.27K | ▲ 19.47K |
| Independent Advisor Alliance | 45.00K | ▲ 45.00K |
| Rs Crum Inc. | 43.24K | ▲ 2.98K |
| Srs Capital Advisors, Inc. | 37.34K | 0 |
| Vanguard Group Inc | 34.73K | 0 |
| Private Advisor Group, LLC | 30.00K | ▲ 30.00K |
| Vanguard Capital Management LLC | 25.51K | 0 |
| Belpointe Asset Management LLC | 19.92K | 0 |
| Northern Trust Corp | 17.76K | 0 |
| Morgan Stanley | 13.24K | ▲ 3.78K |
Held by 6 ETFs
Biggest fund positions in CLDI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | Peoples George | other | 4,000 |
| Aug 17, 26 | Leftwich Scott | other | 4,000 |
| Aug 17, 26 | Stewart Alan R. | other | 4,000 |
| Aug 17, 26 | Jackson Andrew C. | other | 14,000 |
| Aug 17, 26 | Schoeneck James A | other | 5,000 |
| Aug 17, 26 | Poma Eric E | other | 32,000 |
| Aug 17, 26 | Fernandez Santidrian Antonio | other | 16,000 |
| Aug 17, 26 | Sanders Corazon (Corsee) D. | other | 6,000 |
| Jun 17, 26 | Sanders Corazon (Corsee) D. | other | 0 |
| Dec 12, 25 | Camaisa Allan | sell | 850 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLDI coverage
Recent articles, reports, and earnings notes.
No research on CLDI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLDI report →Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
globenewswire.com · Sep 25
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
globenewswire.com · Sep 17
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 8
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · Aug 13
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
globenewswire.com · Jul 27
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
globenewswire.com · Jul 21
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
globenewswire.com · Jul 20
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
globenewswire.com · Jul 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.